Robbins Geller Rudman & Dowd LLP Announces Opportunity for GoodRx Holdings, Inc. Investors Who Suffered Substantial Losses to File Class Action Lawsuit



SAN DIEGO, April 27, 2024 (GLOBE NEWSWIRE) — Law Firm Robbins Geller Ruderman & Dodd LLP Announcing the GoodRx class action lawsuit filed on behalf of purchasers of GoodRx Holdings, Inc. (NASDAQ: GDRX) common stock between September 23, 2020 and November 8, 2022, both dates inclusive, or Acquirers (Class Period) ending June 21, 2024 seeks to be appointed as lead plaintiff in the GoodRx class action lawsuit. The GoodRx class action lawsuit, titled Barsuli v. GoodRx Holdings, Inc., No. 24-cv-03282 (Cal. CD), alleges that GoodRx and certain of GoodRx's officers and directors violated the Securities Exchange Act of 1934.

If you have suffered significant losses and wish to serve as lead plaintiff good receiver CLASS ACTION, PLEASE PROVIDE YOUR INFORMATION HERE:

https://www.rgrdlaw.com/cases-goodrx-holdings-inc-class-action-lawsuit-gdrx.html

You can also contact a lawyer J.C. Sanchez or Jennifer N. Carringer To contact Robbins Geller, call 800/449-4900 or email info@rgrdlaw.com.lead plaintiff motion good receiver The class action lawsuit must be filed in court by June 21, 2024.

Allegations in the case: GoodRx operates a prescription drug price comparison platform that, in many cases, provides consumers with lower drug prices (through discount codes and coupons). GoodRx also generates some of its revenue from subscription programs such as the Kroger (NYSE:) Rx Savings Club, which provides access to [to] Reduce prescription prices at pharmacies operated by The The Kroger Company .

The GoodRx class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) while Kroger represented less than 5% of pharmacies that accepted GoodRx discounts, However, Kroger is responsible for nearly 25% of GoodRx's total prescription drug transaction revenue (Kroger's main source of revenue); (ii) Kroger can unilaterally stop accepting GoodRx discounts, thereby cutting off GoodRx's portion of purchases at Kroger pharmacies; or All income.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

The GoodRx class action lawsuit further alleges that on May 9, 2022, GoodRx disclosed that at the end of the first quarter of 2022, a grocery chain took actions that affected a majority of people from accepting discounts. [pharmacy benefit managers (PBMs)] For a subset of drugs, this affected the grocer's acceptance of many PBM discounts on certain drugs, a disruption that could have an impact of approximately $30 million on second-quarter 2022 revenue, leading GoodRx to announce second-quarter results. Disappointing 2022 revenue guidance of only about $190 million, according to the complaint, GoodRx co-CEO and defendant Trevor Bezdek also acknowledged that the grocery chain's “analysts and media approval” Kroger's use of GoodRx discounts accounted for nearly 25% of GoodRx's prescription drug transaction revenue. According to the GoodRx class action lawsuit, the price of GoodRx common stock fell by more than 25% as a result of this news.

Subsequently, GoodRx class action lawsuit further alleges that on November 8, 2022, GoodRx estimated the impact of grocer issues on third quarter [prescription transactions revenue] About $40 million, GoodRx expects fourth-quarter 2022 prescription drug transaction revenue to be impacted by $45 million to $50 million. ,future. According to the GoodRx class action lawsuit, the price of GoodRx common stock fell by more than 22% as a result of this news.

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

Lead Plaintiff Proceedings: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired shares of GoodRx common stock during the Class Period to seek appointment as lead plaintiff in a GoodRx class action lawsuit. The lead plaintiff is typically the mover with the greatest financial interest in the relief sought by the putative class and is typical and adequate of the putative class. The lead plaintiff leads the GoodRx class action on behalf of all other class members. Lead plaintiffs may file the GoodRx class action lawsuit with the law firm of their choice. An investor's ability to share in any potential future recovery is not contingent upon serving as lead plaintiff in the GoodRx class action lawsuit.

About Robbins Geller: Robbins Geller Rudman & Dowd LLP is one of the world's leading complex class action firms representing plaintiffs in securities fraud cases. The firm is ranked No. 1 in the ISS Securities Class Action Services Top 50 report, recovering more than $1.75 billion for investors in 2022, ranking Robbins Geller at the top of the list for the third consecutive year. In these three years alone, Robbins Geller recovered nearly $5.3 billion for investors, more than twice the amount recovered by other plaintiff firms. With 10 offices and 200 attorneys, Robbins Geller is one of the largest plaintiffs firms in the world, and the firm's attorneys have secured many of the largest securities class action recoveries in history, including the largest ever, The amount is “US$7.2 billion.” litigation. Please visit the following pages for more information:

3rd party advertising. Not an offer or recommendation by Investing.com.See disclosures here or
Remove ads
.

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Lawyer advertising.
Past results are no guarantee of future results.
Services can be provided by attorneys in any of our offices.

touch:
Robbins Geller Ruderman & Dodd LLP
J.C. Sanchez, Jennifer N. Carringer
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
info@rgrdlaw.com





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *